MentiNova Inc.
Repurposed drug treats L-dopa-induced dyskinesia
This article was originally published in Start Up
Executive Summary
For the past 50 years, levodopa, a dopamine precursor, has been the gold-standard treatment for people with Parkinson’s disease-, but there is a significant downside---a condition known as L-dopa-induced dyskinesia that emerges after using this medication for some time. MentiNova Inc., a clinical-stage, New Jersey-based biotechnology company, is repurposing the analgesic nalbuphine for the treatment of LID.